Lunai Bioworks signs exclusive Tanaist deal to expand Parkinson’s platform

Lunai Bioworks (Nasdaq: LNAI) says an exclusive worldwide agreement with Tanaist adds human cellular validation to its AI-driven Parkinson’s workflow, linking patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets.